Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder

American Journal of Transplantation

Volumn 11, Issue 2, 2011, Pages 336-347

  Reshef, R ^a,b   Vardhanabhuti, S ^b   Luskin, M R ^b   Heitjan, D F ^a,b   Hadjiliadis, D ^b   Goral, S ^b   Krok, K L ^b   Goldberg, L R ^b   Porter, D L ^a,b   Stadtmauer, E A ^a,b   Tsai, D E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Immunosuppression; PTLD; solid organ transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KAPLAN-MEIER ESTIMATE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTS; TREATMENT OUTCOME;

EID: 79551501550     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03387.x     Document Type: Article

References (49)

1. Frey NV, Tsai DE,. The management of posttransplant lymphoproliferative disorder. Med Oncol 2007; 24: 125-136.
2. Swerdlow SH,; International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th Ed. Lyon, France: International Agency for Research on Cancer, 2008.
3. Yang J, Tao Q, Flinn IW, et al,. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055-4063.
4. Thorley-Lawson DA, Gross A,. Persistence of the Epstein-Barr virus and the origins of associated lymphomas [see comment]. N Engl J Med 2004; 350: 1328-1337.
5. Starzl TE, Nalesnik MA, Porter KA, et al,. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
6. Tsai DE, Stadtmauer EA, Canaday DJ, Vaughn DJ,. Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder. Med Oncol 1998; 15: 279-281.
7. Benkerrou M, Jais JP, Leblond V, et al,. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998; 92: 3137-3147.
8. Elstrom RL, Andreadis C, Aqui NA, et al,. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576.
9. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E,. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998; 352: 1285.
10. Loren AW, Tsai DE,. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005 vii; Dec; 26: 631-645.
11. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI,. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333-3340.
12. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW,. Lymphoma after solid organ transplantation: Risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27: 3354-3362.
13. Tsai DE, Hardy CL, Tomaszewski JE, et al,. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
14. Issa N, Amer H, Dean PG, et al,. Posttransplant lymphoproliferative disorder following pancreas transplantation. Am J Transplant 2009; 9: 1894-1902.
15. Aversa SM, Stragliotto S, Marino D, et al,. Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: Presentation and response to treatment. Acta Haematol 2008; 120: 36-46.
16. Swinnen LJ, LeBlanc M, Grogan TM, et al,. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008; 86: 215-222.
17. Patel H, Vogl DT, Aqui N, et al,. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases. Leuk Lymphoma 2007; 48: 885-891.
18. Chen JM, Barr ML, Chadburn A, et al,. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993; 56: 527-538.
19. Evens AM, David KA, Helenowski I, et al,. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038-1046.
20. Herzig KA, Juffs HG, Norris D, et al,. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int 2003; 16: 529-536.
21. Gill D, Juffs HG, Herzig KA, et al,. Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation. Transplant Proc 2003; 35: 256-257.
22. Caillard S, Lelong C, Pessione F, Moulin B,. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735-2742.
23. Cohen JI,. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Med (Baltimore) 1991; 70: 137-160.
24. Finn L, Reyes J, Bueno J, Yunis E,. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998; 22: 299-309.
25. Shroff R, Trompeter R, Cubitt D, Thaker U, Rees L,. Epstein-Barr virus monitoring in paediatric renal transplant recipients. Pediatr Nephrol 2002; 17: 770-775.
26. Sokal EM, Antunes H, Beguin C, et al,. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438-1442.
27. Shahinian VB, Muirhead N, Jevnikar AM, et al,. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851-856.
28. Foroncewicz B, Mucha K, Usiekniewicz J, et al,. Posttransplant lymphoproliferative disorder of the lung in a renal transplant recipient treated successfully with surgery. Transplant Proc 2006; 38: 173-176.
29. Hauke R, Smir B, Greiner T, et al,. Clinical and pathological features of posttransplant lymphoproliferative disorders: Influence on survival and response to treatment. Ann Oncol 2001; 12: 831-834.
30. Mucha K, Foroncewicz B, Niemczyk K, et al,. Tonsil enlargement after liver transplantation in adults-Reason enough for tonsillectomy? Two cases of tonsillar posttransplantation lymphoproliferative disease. Liver Transpl 2007; 13: 918-923.
31. Beynet DP, Wee SA, Horwitz SS, et al,. Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Arch Dermatol 2004; 140: 1140-1146.
32. Trofe J, Buell JF, Beebe TM, et al,. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5 (4 Pt 1): 775-780.
33. Hanto DW,. Retransplantation after post-transplant lymphoproliferative diseases (PTLD): When is it Safe? Am J Transplant 2004; 4: 1733-1734.
34. Johnson SR, Cherikh WS, Kauffman HM, Pavlakis M, Hanto DW,. Retransplantation after post-transplant lymphoproliferative disorders: An OPTN/UNOS database analysis. Am J Transplant 2006; 6: 2743-2749.
35. Reshef R, Luskin M, Morgans A, et al,., editors. EBV-Negative PTLD: 20 Year Experience in a Large Transplant Center. American Transplant Congress; 2009 May 30-June 3; Boston, MA: Wiley-Blackwell Publishing, Inc.
36. Tsai DE, Douglas L, Andreadis C, et al,. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: Results of a two-arm prospective trial. Am J Transplant 2008; 8: 1016-1024.
37. Guppy AE, Rawlings E, Madrigal JA, Amlot PL, Barber LD,. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8 +T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation 2007; 84: 1534-1539.
38. Maecker B, Jack T, Zimmermann M, et al,. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007; 25: 4902-4908.
39. Buell JF, Gross TG, Hanaway MJ, et al,. Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement. Transplant Proc 2005; 37: 954-955.
40. Leblond V, Dhedin N, Mamzer Bruneel MF, et al,. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772-778.
41. Choquet S, Mamzer BM, Hermine O, et al,. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 67-80.
42. Ghobrial IM, Habermann TM, Macon WR, et al,. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases? Transplantation 2005; 79: 244-247.
43. Fischer A, Blanche S, Le Bidois J, et al,. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451-1456.
44. Milpied N, Vasseur B, Parquet N, et al,. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113-116.
45. Choquet S, Leblond V, Herbrecht R, et al,. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
46. Cheson BD, Leonard JP,. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359: 613-626.
47. Oertel SH, Verschuuren E, Reinke P, et al,. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906.
48. Aull MJ, Buell JF, Trofe J, et al,. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004; 78: 1676-1682.
49. Issa N, Amer H, Dean PG, et al,. Posttransplant lymphoproliferative disorder following pancreas transplantation. Am J Transplant 2009; 9: 1894-1902.